

CURRICULUM VITAE OF ROBERTO BADAGLIACCA

Identification

Born in Rome, July 27 1973.

Lives in Rome.

Private address: Via Nomentana n.891, 00137 Rome, Italy.
Ph. ++39 06 8277832, *cell.* 3393794079.
e-mail: roberto.badagliacca@uniroma1.it

Work address: Dep.of Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari
University of Rome "Sapienza", 00161 Rome, Italy
Ph. ++39 06 49979021 *fax.* ++39 06 49979060

Private Office: Viale del Policlinico n.129A
Phone number: +39 064402727

Education

- High School ("Classical Sciences" Major): "Istituto San Leone Magno", Rome, July 23 1992. Final grade: 60/60.
- Medical Doctor [M.S. Degree in Medicine and Surgery at the University of Rome "La Sapienza", October 28 1998. Final grade: 110/110 cum laude (course grade average 29,8/30)].
- Passed the Medical Bar exam in Rome, July 23 1999.
- Enrolled in the Medical Association of Rome since February 7 2000.
- Certified BLS (Basic Life Support-Defibrillation) operator, Rome March 11 2002.
- Specialized in Cardiology (Board Certification) at the University of Rome "La Sapienza", 1st School of Cardiology, November 24 2002. Final grade: 70/70 cum laude.
- Ph.D. in Cardiovascular and Respiratory Pathophysiology at the University of Rome "La Sapienza", 1st School of Cardiology, July 13 2006.
- Masterclasses in "Pulmonary Arterial Hypertension", Erasme University Hospital, Free University Brussels, 2008-2009-2010-2011-2013.
- Fellowship at the Department of Physiology and Pathophysiology, Pulmonary Hypertension Clinic Erasmus Hospital, Free University Brussels, for 12 months from 2013 to 2017.
- Fellowship at the Referral Centre for Pulmonary Hypertension, Bicetre Hospital, University of Paris-Sud, France, June 2013.
- I Level Degree in Cardiovascular Magnetic Resonance, certified by the European Association of Cardiovascular Imaging, European Society of Cardiology.

Thesis of Specialization

- Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue: idiopathic versus chronic thromboembolic pulmonary hypertension.

- Casa di Cura Santa Famiglia as Cardiologist in Cardiological Rehabilitation Unit, from June 2003 to March 2008.
- Sanitary Aid FOR.COM (University Consortium) as Cardiologist, from January 2003 to December 2007.

Associative activity

Member of the following Societies and Associations:

- Italian Society of Cardiology (S.I.C.)
- Italian Society of Cardiovascular Echography (S.I.E.C.)
- International Society of Heart and Lung Transplantation (I.S.H.L.T.)
- Pulmonary Vascular Research Institute (PVRI)
- Pulmonary Hypertension Patients Association (A.M.I.P.)

Research activity and responsibilities

FIELDS OF INTEREST: Heart failure, pulmonary hypertension, right ventricular physiology and pathophysiology.

- Nucleus Member of the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, 2020-2022.
- Treasurer of the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, since 2023.
- Task Force member to develop the 2022 European Society of Cardiology (ESC) / European Respiratory Society (ERS) GUIDELINES for the Diagnosis and Treatment of Pulmonary Hypertension. 2020-2022.
- Co-Chair of the core-Lab for centralized reading of the echocardiographic testing of the United States Pulmonary Hypertension Scientific Registry (USPHSR). PHORA Project (Pulmonary Hypertension Outcomes Risk Assessment): A Clinical Decision Support Tool for Patients with Pulmonary Arterial Hypertension, National Institute of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) (R01HL134673).
- Working Group Member of the International Society of Heart and Lung Transplantation (ISHLT) CONSENSUS STATEMENT: Peri-operative Management of Patients with Pulmonary Hypertension and Right Heart Failure Undergoing Surgery (2021).
- Working Group Member of the International Society of Heart and Lung Transplantation CONSENSUS STATEMENT: Risk Stratification in Pulmonary Arterial Hypertension (2022).
- 2021-2022 Project Leader. POSITION PAPER on Echocardiographic evaluation of patients with pulmonary arterial hypertension. ESC Working Group on Pulmonary Circulation and Right Ventricular Function in collaboration with the European Association of Cardiovascular Imaging (EACVI). Work in progress.
- 2021 Task Force member of the Innovative Drug Development Initiative for the Pulmonary Vascular Research Institute (PVRI) on Clinical Trial Design. Work in progress.
- Task Force member of the Innovative Drug Development Initiative for the Pulmonary Vascular Research Institute on Consolidated Device Development. Work in progress.
- President and founding partner of Ma.CRO LifeScience, a University Sapienza Startup created in 2019. In collaboration with AMID srl and Medis Medical Imaging.

- Member of the Sotatercept - Advisory Board, organized by Acceleron. 26 March 2021 (virtual meeting).
- Member of the Advisory Board on Riociguat in PAH, organized by MSD. Rome, 31 May 2021.
- Member of the AB TripleTRE parenteral treprostinil in PAH. 15 June 2022 (on-line meeting).
- Member of the EU PAH Advisory Board for the TripleTRE trial. AOP, 23rd November 2023.
- Member of the Advisory board “Una nuova era nel trattamento dell’ipertensione arteriosa polmonare: il ruolo di Sotatercept”. Rome, 27th November 2023.

Clinical Trials

- **Principal Investigator:** Arena APD811-301: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH)-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
- **Principal Investigator:** Arena APD811-302: A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of initial ralinepag, ambrisentan and tadalafil combination therapy versus ambrisentan and tadalafil combination therapy in treatment naïve patients with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH).
- **Principal Investigator:** AC-065B302: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, phase 3 study with open-label extension period to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension.
- **Principal Investigator:** Investigator-Initiated Study: “Studio di follow-up per valutare l’impatto prognostico della terapia specifica per l’ipertensione arteriosa polmonare sul rimodellamento del ventricolo destro: monoterapia verso terapia di combinazione”. Ethical Committee approval CE 4304. Contract n. 8/2017, University of Rome “Sapienza”, Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche. From 25-08-2016.
- **Principal Investigator:** Investigator-Initiated Study: “Parenteral Prostanoids in PAH: Instructions for Complete Benefits” (ID: 39AB01FC-137C-4E09-80C3-13D547D2F27F). EC approval (CE 4303). Contract n. 5/2017, University of Rome “Sapienza”, Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche. From 09-02-2017.
- **Principal Investigator** (DR n. 2936/2017): University Research Grant (DR 1052/2017): Right ventricular dyssynchrony evaluation in pulmonary arterial hypertension treated patients. From 20-11-2017.
- **Principal Investigator** (Delibera S.A. n. 340/18): University Research Grant: Right ventricular echocardiographic evaluation in pulmonary hypertension: right ventricular adaptation to increased afterload and risk stratification..From 06/11/2018.
- **Principal Investigator** (protocol n. RG118164367CF399): University Research Grant: Validation of a New Specific Activity Scale for Assessing Cardiovascular Functional Class in Pulmonary Arterial Hypertension: advantages in prognostic stratification. From 26/02/2019.
- **Member of the Steering Committee:** CTEPH SOLUTION: “Evidenced-based detection of CTEPH in patients with prior pulmonary embolism: risk SCORE evaluation and

- at -BAY63-2521- (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension; Protocollo 11348).
- Co-Investigator in the study NCT00477269 (A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor Imatinib -STI571- for the Treatment of Pulmonary Arterial Hypertension).
 - Co-Investigator in the study RELAX-AHFA (Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure).
 - Co-Investigator in the study BALANCE (Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to determine the safety and efficacy of Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation).
 - Co-Investigator in the study ASCEND-HF (Double-Blind, Placebo-Controlled, Multi-center Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure).
 - Co-Investigator N° 12935 (PATENT-2): “Long-term extension, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)”. From 01-03-2009 to 01-06-2016.
 - Co-Investigator FREEDOM-C1: “A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension”. A MULTINATIONAL, MULTICENTRE, RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH). From 01-06-2009 to 01-07-2011.
 - Co-Investigator CHEST-2 Study (Open Label, Multi-centre, Multi-national Study to Evaluate long term the Efficacy and Safety of Oral Riociguat -BAY63-2521- (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension). From 01-07-2009.
 - Co-Investigator N° CQTI571A2301 (IMPRES): “A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study”. From 01-09-2009 to 01-05-2011.
 - Co-Investigator N° CQTI571A2301E1: “An extension study to CQTI571A2301 to evaluate the long-term safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES extension”. From 01-04-2010 to 01-04-2014.
 - Co-Investigator N° AMB112565 (AMBITION): “A randomized, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension”. From 01-10-2010 to 01-08-2014.
 - Co-Investigator SPHERIC-1: “Studio multicentrico, randomizzato, a doppio cieco, verso placebo, della durata di 16 settimane che valuta l’effetto del sildenafil nel trattamento di paziente con ipertensione polmonare associata a BPCO”. From 01-10-2010 to 01-02-2013.
 - Co-Investigator N° CQTI571A2102: “A non randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-administered drugs sildenafil and bosentan in pulmonary arterial hypertension (PAH) patients”. From 01-04-2011 to 01-07-2012.

10. The importance of the right ventricle in pulmonary arterial hypertension. ESC Congress, 27th August 2018, Munich.
11. Regional right ventricular function: how does it affect pathophysiology. 7th European Symposium on the Right Ventricle in Pulmonary Hypertension, 10th October 2018, Royal College of Physicians, London, NW1 4LE.
12. The importance of RV function evaluation in PAH and its role for treatment strategies. 6th Clinical Seminar in Pulmonary Hypertension e thromboembolic disease. Salonicco, 1-3 November 2018.
13. The best timing for treatment escalation. 10th Annual Central European PH Meeting, Vienna, 30th November-2nd December 2018.
14. Lecture: Acute and long-term management of PAH, Bundang Seoul National University Hospital, Seoul, 16th January 2019.
15. Lecture: Prognostic factors in severe pulmonary hypertension, Samsung Seoul Medical Center, Seoul, 19th January 2019.
16. Lecture: Early and aggressive treatment in PAH: time for RV integration to risk assessment, 14th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease, London, March 9th 2019.
17. Lecture: The importance of right ventricular evaluation in PAH: time for imaging integration in risk assessment. PULMONARY HYPERTENSION SCIENTIFIC SYMPOSIUM held in Budapest, Hungary, 18th April 2019.
18. CTEPH Solution. Preliminary data. Gap of evidence in pulmonary hypertension. The usefulness of registries. Pulmonary Vascular Research Institute European Task Force 2019 Meeting. Catania, 11th October 2019.
19. Lecture: Early and aggressive treatment in PAH: time for RV integration to risk assessment. Latin America IMPAHCT. International Meeting on PAH Clinical Treatment. 24-26th October 2019, Buenos Aires. Argentina.
20. Meet the expert workshop. Latin America IMPAHCT. International Meeting on PAH Clinical Treatment. 24-26th October 2019, Buenos Aires. Argentina.
21. Invited Speaker: Monitoring RV function and RV-PA coupling via non-invasive and invasive modalities. AHA (American Heart Association) Congress 2019, Philadelphia, 16-18th November 2019.
22. Can we improve risk stratification. 11th Annual Central European PH Meeting, Vienna, 22-24th November 2019.
23. European Respiratory Society - Pulmonary hypertension & pulmonary vascular disease Course, Lausanne, Switzerland, 27-29th February 2020.
24. Lecture: The importance of parenteral prostanoids for right ventricular reverse remodeling and improved outcome. VIII Congreso Internacional de Falla Cardíaca, Trasplante Cardíaco e Hipertensión Pulmonar. Cartagena. Colombia. 25th November 2021.
25. Lecture: Risk reduction – which goals should be achieved? 13th Annual Central European PH Meeting, Vienna, 26-27th November 2021.
26. Lecture: PAH treatment strategy and parenteral treprostinil management. Medical Education Program for cardiologists and pulmonologists. Costa Rica. 23rd March 2022.
27. Lecture: Imaging of Improved Right Ventricular Coupling, Risk Status and Survival in Pulmonary Arterial Hypertension. International Society Heart and Lung Transplantation 42nd Annual Meeting and Scientific Sessions. 27-30 April 2022. Boston, MA, USA.

Solutions -Perioperative State. Saudi Thoracic Society International Conference 2023. Riyadh, Saudi Arabia, 9-12 november 2023.

44. Lecture: Relevance of right ventricular imaging for risk stratification in PAH. VIII Summit on Heart Failure, Cardiomyopathies, and Pulmonary Hypertension. Argentina, 27th-30th November 2023 (virtual).
45. Lecture: Normalizar la presión pulmonar. ¿nuevo objetivo terapéutico? V Jornada Internacional de “Abordaje Multidisciplinar en la Hipertensión Pulmonar” . Hospital Universitario 12 de Octubre. Madrid, 1st december 2023.
46. Lectures: 1- Importance of imaging for proper risk scoring; 2-The effect of an aggressive treatment approach on the right ventricle. 15° European Pulmonary Hypertension Meeting. Vienna, 1-2 dicembre 2023.
47. Lecture: IPAH with left heart phenotype vs. group 2 PH: how to differentiate, how to treat? Congress “PAH 3600 challenge for all ages”. Vienna, 18-19 gennaio 2024.

National Congresses

Faculty member of more than 150 National Congresses and Symposia, as a Chair, Co-Chair, and Speaker, since 2002.

Publications in indexed Journals

Top-1% rated expert in Right Ventricular Dysfunction in the world during the years 2010-2020, according to the expertscape's PubMed-based algorithms.

Top-1% rated expert in Pulmonary Arterial Hypertension in the world during the years 2010-2020, according to the expertscape's PubMed-based algorithms.

1. Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D, **Badagliacca R**, Vestri AR, Naeije R, Fedele F. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. *Heart*. 2001 Dec;86(6):661-5. (IF 5.4)
2. C.D. Vizza, C. Letizia, S. Sciomer, R. Naeije, G. Della Rocca, A. Di Roma, S. Musarò, S. Quattrucci, C. Gaudio, A. Battagliese, **R. Badagliacca**, E. D’Erasmus, F. Fedele. *Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease*. *Regul Pept* 2005; 124:187-193. (IF 1.8)
3. E. Nicastrì, C.D. Vizza, F. Carletti, S. Cicalini, **R. Badagliacca**, R. Poscia, G. Ippolito, F. Fedele, N. Petrosillo. *Human Herpesvirus 8 and pulmonary hypertension*. *Emerging Infectious Diseases* 2005; 11 (9): 1480-1482. (I.F. 7.4)
4. S. Sciomer, R. Badagliacca, F. Fedele. *Pulmonary hypertension: echocardiographic assessment*. *Ital Heart J* 2005; 6: 840-845.
5. Vizza CD, Letizia C, **Badagliacca R**, Sciomer S, Poscia R, Della Rocca G, Iacoboni C, Leonardo de L, Quattrucci S, Dario C, Luigi P, Fedele F. Plasma adrenomedullin and endothelin-1 concentration during low-dose dobutamine infusion: Relationship between pulmonary uptake and pulmonary vascular pressure/flow characteristics. *Regul Pept*. 2006 Sep 11;136(1-3):85-91.
6. Vizza CD, **Badagliacca R**, Sciomer S, Poscia R, Battagliese A, Schina M, Agati L, Fedele F. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. *Cardiology*. 2006;106(3):168-73. (IF 1.7)

21. Frustaci A, Petrosillo N, Vizza D, Francone M, **Badagliacca R**, Verardo R, Fedele F, Ippolito G, Chimenti C. Myocardial and microvascular inflammation/infection in patients with HIV-associated pulmonary artery hypertension. *AIDS*. 2014 Aug 19. [Epub ahead of print] PubMed PMID: 25144217. (I.F. 4.9)
22. **Badagliacca R**, Poscia R, Pezzuto B, Papa S, Gambardella C, Francone M, Mezzapesa M, Nocioni M, Nona A, Rosati R, Sciomer S, Fedele F, Dario Vizza C. Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: Determinants and impact on pump function. *J Heart Lung Transplant*. 2015 Mar;34(3):381-9
23. Mantegazza V, **Badagliacca R**, Nodari S, Parati G, Lombardi C, Di Somma S, Carluccio E, Dini FL, Correale M, Magri D, Agostoni P. Management of heart failure in the new era: the role of scores. *J Cardiovasc Med (Hagerstown)*. 2016 Aug;17(8):569-80 (I.F. 1.61)
24. D'Alto M, Romeo E, Argiento P, Di Salvo G, **Badagliacca R**, Cirillo AP, Kaemmerer H, Bossone E, Naeije R. Pulmonary Arterial Hypertension: The Key Role of Echocardiography. *Echocardiography*. 2015 Jan;32 Suppl 1:S23-37. (I.F. 1.31)
25. Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall'Armi V, **Badagliacca R**, Barbagallo F, Lenzi A, Isidori AM. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. *BMC Med*. 2014 Oct 20;12(1):185. [Epub ahead of print] PubMed PMID:25330139; PubMed Central PMCID: PMC4201993. (I.F. 9.0)
26. **Badagliacca R**, Poscia R, Pezzuto B, Nocioni M, Mezzapesa M, Francone M, Giannetta E, Papa S, Gambardella C, Sciomer S, Volterrani M, Fedele F, Dario Vizza C. Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. *J Heart Lung Transplant*. 2015 Mar;34(3):395-403. doi: 10.1016/j.healun.2014.11.002. Epub 2014 Nov 8. PubMed PMID: 25499139.
27. Pezzuto B, **Badagliacca R**, Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD. Circulating biomarkers in pulmonary arterial hypertension: update and future direction. *J Heart Lung Transplant*. 2015 Mar;34(3):282-305.
28. Stefanantoni K, Sciarra I, Vasile M, **Badagliacca R**, Poscia R, Pendolino M, Alessandri C, Vizza CD, Valesini G, Ricciari V. Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. *Reumatismo*. 2015 Mar 31;66(4):270-6.
29. **Badagliacca R**, Reali M, Poscia R, Pezzuto B, Papa P, Mezzapesa M, Nocioni M, Valli G, Giannetta E, Sciomer S, Iacoboni C, Fedele F, Vizza CD. Right intraventricular dyssynchrony in idiopathic, heritable and anorexigen-induced pulmonary arterial hypertension: clinical impact and reversibility. *JACC Cardiovasc Imaging*. 2015 Jun;8(6):642-52. (I.F. 10.2)
30. Pofi R, Gianfrilli D, **Badagliacca R**, Di Dato C, Venneri MA, Giannetta E. Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work? *J Endocrinol Invest*. 2016 Feb;39(2):131-42. (I.F. 2.63)
31. Della Rocca G, Vetrugno L, Coccia C, Pierconti F, **Badagliacca R**, Vizza CD, Papale M, Melis E, Facciolo F. Preoperative Evaluation of Patients Undergoing Lung Resection Surgery: Defining the Role of the Anesthesiologist on a Multidisciplinary Team. *J Cardiothorac Vasc Anesth*. 2016 Apr;30(2):530-8. doi:10.1053/j.jvca.2015.11.018. Epub 2015 Dec 1. Review. PubMed PMID: 27013123. (I.F. 1.69)
32. **Badagliacca R**, Poscia R, Pezzuto B, Papa S, Pesce F, Manzi G, Giannetta E, Raineri C, Schina M, Sciomer S, Parola D, Francone M, Carbone I, Fedele F, Vizza CD. Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. *J Heart Lung Transplant*. 2016 Nov;35(11):1321-1329.
33. Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggioni T, Rottoli P, Paciocco G, Tuzzolino F, Martino L, Beretta M, Callari A, Amaducci A, **Badagliacca R**, Poscia R, Meloni F, Refini RM, Geri P, Baldi S, Ghio S, D'Alto M, Argiento P, Sofia M, Guardamagna

- chronic heart failure with reduced ejection fraction: a long-term comparison. *Eur J Heart Fail*. 2017 Sep 26. doi: 10.1002/ejhf.989.
42. Naeije R, **Badagliacca R**. The overloaded right heart and ventricular interdependence. *Cardiovasc Res*. 2017 Oct 1;113(12):1474-1485. (I.F. 5.87)
 43. **Badagliacca R**, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, Manzi G, Gianfrilli D, Ciociarello F, Sciomer S, Biondi-Zoccai G, Torre R, Fedele F, Vizza CD. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. *J Heart Lung Transplant*. 2017 Oct 2. pii:S1053-2498(17)32041-7.
 44. Pezzuto B, **Badagliacca R**, Poscia R, Torre R, Ghio S, Scelsi L, Greco A, D'Alto M, Argiento P, Vitulo P, Fedele F, Dario Vizza C. [Oral combination therapy for the treatment of patients with pulmonary arterial hypertension: what evidence from long-term studies?]. *G Ital Cardiol (Rome)*. 2017 Dec;18(12):854-861.
 45. D'Alto M, Romeo E, Argiento P, Paciocco G, Prediletto R, Ghio S, Correale M, Lo Giudice F, **Badagliacca R**, Greco A, Vizza CD. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study). *J Cardiovasc Med (Hagerstown)*. 2018 Jan;19(1):12-17.
 46. Vizza CD, **Badagliacca R**, Messick CR, Rao Y, Nelsen AC, Benza RL. The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. *Int J Cardiol*. 2018 Mar 1;254:299-301.
 47. Bruno N, Sinagra G, Paolillo S, Bonomi A, Corrà U, Piepoli M, Veglia F, Salvioni E, Lagioia R, Metra M, Limongelli G, Cattadori G, Scardovi AB, Carubelli V, Scrutinio D, **Badagliacca R**, Guazzi M, Raimondo R, Gentile P, Magri D, Correale M, Parati G, Re F, Cicoira M, Frigerio M, Bussotti M, Vignati C, Oliva F, Mezzani A, Vergaro G, Di Lenarda A, Passino C, Sciomer S, Pacileo G, Ricci R, Contini M, Apostolo A, Palermo P, Mapelli M, Carriere C, Clemenza F, Binno S, Belardinelli R, Lombardi C, Perrone Filardi P, Emdin M, Agostoni P. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. *ESC Heart Fail*. 2018 Jun;5(3):267-274.
 48. Farina S, Correale M, Bruno N, Paolillo S, Salvioni E, **Badagliacca R**, Agostoni P; "Right and Left Heart Failure Study Group" of the Italian Society of Cardiology. The role of cardiopulmonary exercise tests in pulmonary arterial hypertension. *Eur Respir Rev*. 2018 May 2;27(148). pii: 170134.
 49. Ghio S, Fortuni F, Greco A, Turco A, Lombardi C, Scelsi L, Raineri C, Matrone B, Vullo E, Guida S, **Badagliacca R**, Oltrona Visconti L. Dobutamine stress echocardiography in pulmonary arterial hypertension. *Int J Cardiol*. 2018 Jun 8. pii: S0167-5273(18)32013-8.
 50. Vizza C.D., **Badagliacca R**. Oxygen supplementation for PAH ? Clues from the REVEAL registry. *J Heart Lung Transplant*. 2018 Aug;37(8):941-942. doi: 10.1016/j.healun.2018.06.003.
 51. Naeije R, Vanderpool R, Peacock A, **Badagliacca R**. The Right Heart-Pulmonary Circulation Unit: Physiopathology. *Heart Fail Clin*. 2018 Jul;14(3):237-245. doi: 10.1016/j.hfc.2018.02.001.
 52. Pezzuto B, Forton K, **Badagliacca R**, Motoji Y, Faoro V, Naeije R. Right ventricular dyssynchrony during hypoxic breathing but not during exercise in healthy subjects a speckle tracking echocardiography study. *Exp Physiol*. 2018 Jul 28. doi: 10.1113/EP087027. (I.F. 2.7).
 53. Jeness Campodonico, Massimo Piepoli, Francesco Clemenza, Alice Bonomi, Stefania Paolillo, Elisabetta Salvioni, Ugo Corrà, Simone Binno, Fabrizio Veglia, Rocco Lagioia, Gianfranco Sinagra, Gaia Cattadori, Angela B. Scardovi, Marco Metra, Michele Senni, Domenico Scrutinio, Rosa Raimondo, Michele Emdin, Damiano Magri, Gianfranco Parati, Federica Re, Mariantonietta Cicoira, Chiara Minà, Giuseppe Limongelli, Michele Correale, Maria Frigerio, Maurizio Bussotti, Enrico Perna, Elisa Battaia, Marco Guazzi, **R. Badagliacca**, Andrea Di Lenarda, Aldo Maggioni, Claudio Passino, Susanna Sciomer, Giuseppe Pacileo, Massimo Mapelli, Carlo Vignati, Carlo Lombardi, Pasquale Perrone Filardi, Piergiuseppe

- from the MECKI score research group. *Eur J Intern Med.* 2019 Nov 28. pii: S0953-6205(19)30390-5. doi:10.1016/j.ejim.2019.11.003.
64. **Badagliacca R**, Papa S, Matsubara H, Lang IM, Poscia R, Manzi G, Vizza CD. The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. *Int J Cardiol.* 2020 Feb 15;301:183-189. doi: 10.1016/j.ijcard.2019.10.043. Epub 2019 Nov 13.
 65. Salvioni E, Corrà U, Piepoli M, Rovai S, Correale M, Paolillo S, Pasquali M, Magri D, Vitale G, Fusini L, Mapelli M, Vignati C, Lagioia R, Raimondo R, Sinagra G, Boggio F, Cangiolo L, Gallo G, Magini A, Contini M, Palermo P, Apostolo A, Pezzuto B, Bonomi A, Scardovi AB, Filardi PP, Limongelli G, Metra M, Scrutinio D, Emdin M, Piccioli L, Lombardi C, Cattadori G, Parati G, Caravita S, Re F, Ciccoira M, Frigerio M, Clemenza F, Bussotti M, Battaia E, Guazzi M, Bandera F, **Badagliacca R**, Di Lenarda A, Pacileo G, Passino C, Sciomer S, Ambrosio G, Agostoni P; MECKI score research group. Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. *ESC Heart Fail.* 2020 Jan 1. doi: 10.1002/ehf2.12582.
 66. Sinagra G, Corrà U, Contini M, Magri D, Paolillo S, Perrone Filardi P, Sciomer S, **Badagliacca R**, Agostoni P. Choosing among β -blockers in heart failure patients according to β -receptors' location and functions in the cardiopulmonary system. *Pharmacol Res.* 2020 Mar 26:104785. doi: 10.1016/j.phrs.2020.104785. [Epub ahead of print] Review. PubMed PMID: 32224252.
 67. **Badagliacca R**, Rischard F, Papa S, Kubba S, Vanderpool R, Yuan JX, Garcia JGN, Airhart S, Poscia R, Pezzuto B, Manzi G, Miotti C, Luongo F, Scoccia G, Sciomer S, Torre R, Fedele F, Vizza CD. Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. *J Heart Lung Transplant.* 2020 Apr;39(4):310-320.
 68. **Badagliacca R**, Sciomer S, Petrosillo N. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: friend or foe? *J Heart Lung Transplant.* 2020;39(7):729-730.
 69. Paolillo S, Salvioni E, Perrone Filardi P, Bonomi A, Sinagra G, Gentile P, Gargiulo P, Scoccia A, Cosentino N, Gugliandolo P, **Badagliacca R**, Lagioia R, Correale M, Frigerio M, Perna E, Piepoli M, Re F, Raimondo R, Minà C, Clemenza F, Bussotti M, Limongelli G, Gravino R, Passantino A, Magri D, Parati G, Caravita S, Scardovi AB, Arcari L, Vignati C, Mapelli M, Cattadori G, Cavaliere C, Corrà U, Agostoni P; MECKI score research group (see Appendix A). Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: Insights from the MECKI Score database [published online ahead of print, 2020 Apr 29]. *Int J Cardiol.* 2020;S0167-5273(20)31266-3. doi:10.1016/j.ijcard.2020.04.079
 70. Sciomer S, Moscucci F, Magri D, **Badagliacca R**, Piccirillo G, Agostoni P. SARS-CoV-2 spread in Northern Italy: what about the pollution role?. *Environ Monit Assess.* 2020;192(6):325.
 71. De Lazzari C, De Lazzari B, Iacovoni A, Marconi S, Papa S, Capoccia M, **Badagliacca R**, Vizza CD. Intra-aortic balloon counterpulsation timing: A new numerical model for programming and training in the clinical environment [published online ahead of print, 2020 May 15]. *Comput Methods Programs Biomed.* 2020;194:105537. doi:10.1016/j.cmpb.2020.105537
 72. Magri D, Piepoli M, Corrà U, Gallo G, Maruotti A, Vignati C, Salvioni E, Mapelli M, Paolillo S, Perrone Filardi P, Girola D, Metra M, Scardovi AB, Lagioia R, Limongelli G, Senni M, Scrutinio D, Emdin M, Passino C, Lombardi C, Cattadori G, Parati G, Ciccoira M, Correale M, Frigerio M, Clemenza F, Bussotti M, Guazzi M, **Badagliacca R**, Sciomer S, Di Lenarda A, Maggioni A, Sinagra G, Volpe M, Agostoni P; MECKI score Research Group (see appendix). Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test [published online ahead of print,

- A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Ghofrani HA; Collaborators list. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. *Respir Med.* 2020 Dec 3;177:106241. doi: 10.1016/j.rmed.2020.106241.
85. Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberá JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Hoepfer MM; NEW COLLABORATORS LIST. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. *Respir Med.* 2021 Mar;178:106220. doi: 10.1016/j.rmed.2020.106220.
86. Miotti C, Papa S, Manzi G, Scoccia G, Luongo F, Toto F, Malerba C, Cedrone N, Sciomer S, Ciciarello F, Fedele F, Vizza CD, **Badagliacca R**. The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece. *J Clin Med.* 2021 Feb 6;10(4):619. doi: 10.3390/jcm10040619.
87. Vizza CD, Hoepfer MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, Ghofrani HA, Held M, Klose H, Lange T, Rosenkranz S, Dumitrescu D, **Badagliacca R**, Claussen M, Halank M, Vonk-Noordegraaf A, Skowasch D, Ewert R, Gibbs JSR, Delcroix M, Skride A, Coghlan G, Ulrich S, Opitz C, Kaemmerer H, Distler O, Grünig E. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). *Chest.* 2021 Aug;160(2):678-689
88. De Lazzari B, Iacovoni A, Mottaghy K, Capoccia M, **Badagliacca R**, Vizza CD, De Lazzari C. ECMO Assistance during Mechanical Ventilation: Effects Induced on Energetic and Haemodynamic Variables. *Comput Methods Programs Biomed.* 2021 Apr;202:106003. doi: 10.1016/j.cmpb.2021.106003.
89. Manzi G, Papa S, Vizza CD, **Badagliacca R**. Right ventricular assessment matters for precision medicine. Reply to "Identifying parameters associated with response to switching from a PDE5i to riociguat in RESPITE". *Int J Cardiol.* 2021 Jun 15;333:210. doi: 10.1016/j.ijcard.2021.03.004
90. Miotti C, D'Armini AM, Scardovi B, Ghio S, Sinagra G, Serra W, Romaniello A, Galgano G, Roncon L, D'Alto M, Giannazzo D, Vitulo P, Bongarzone A, Ruzzolini M, Albera C, Casu G, Perazzolo Marra M, Pierdomenico SD, Luongo F, Manzi G, Papa S, Scoccia G, Cedrone N, **Badagliacca R**, Vizza CD. Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH Solution): proposal of a study protocol aimed to realize a validated risk score for early diagnosis. *Minerva Cardiol Angiol.* 2021 Mar 11. doi: 10.23736/S2724-5683.21.05575-7.
91. Miotti C, Papa S, Manzi G, Luongo F, Scoccia G, Vizza CD, **Badagliacca R**. Incidence and long-term outcomes of pregnant women complicated with pulmonary arterial hypertension during different pregnancies: A prospective cohort study from China. *Int J Cardiol.* 2021 Jun 1;332:193-194. doi: 10.1016/j.ijcard.2021.03.068
92. Lavalle C, Magnocavallo M, Straito M, Santini L, Forleo GB, Grimaldi M, **Badagliacca R**, Lanata L, Ricci RP. Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias. *J Clin Med.* 2021 Apr 2;10(7):1456. doi: 10.3390/jcm10071456.
93. **Badagliacca R**, Pezzuto B, Papa S, Naeije R, Vizza CD. The Authors Reply. *JACC Cardiovasc Imaging.* 2021 Jul;14(7):1488-1489. doi: 10.1016/j.jcmg.2021.04.026.
94. Papa S, Miotti C, Manzi G, Scoccia G, Luongo F, Toto F, Malerba C, Cedrone N, Canuti ES, Caputo A, Manguso G, Valentini S, Sciomer S, Ciciarello F, Benedetti G, Fedele F, Vizza CD, **Badagliacca R**. Peripheral Arterial Stiffness in Acute Pulmonary Embolism and Pulmonary Hypertension at Short-Term Follow-Up. *J Clin Med.* 2021 Jul 6;10(14):3008. doi: 10.3390/jcm10143008.

107. De Lazzari, B., Iacovoni, A., Capoccia, M., Papa, S., **Badagliacca, R.**, Filomena, D., & De Lazzari, C. (2022). Ventricular and Atrial Pressure-Volume Loops: Analysis of the Effects Induced by Right Centrifugal Pump Assistance. *Bioengineering (Basel, Switzerland)*, 9(5), 181. <https://doi.org/10.3390/bioengineering9050181> (I.F. 4.48)
108. Pofi, R., Giannetta, E., Feola, T., Galea, N., Barbagallo, F., Campolo, F., **Badagliacca, R.**, Barbano, B., Ciolina, F., Defeudis, G., Filardi, T., Sesti, F., Minnetti, M., Vizza, C. D., Pasqualetti, P., Caboni, P., Carbone, I., Francone, M., Catalano, C., Pozzilli, P., ... Isidori, A. M. (2022). Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. *Science translational medicine*, 14(649), eabl8503. <https://doi.org/10.1126/scitranslmed.abl8503> (I.F. 19.31)
109. Vizza CD, Ghio S, **Badagliacca R**, et al. Gaps of evidence in pulmonary arterial hypertension. *Int J Cardiol.* 2022;364:119-123. doi:10.1016/j.ijcard.2022.06.026 (I.F. 4.16)
110. Manzi, G., Papa, S., Mariani, M. V., Scoccia, G., Filomena, D., Malerba, C., Adamo, F. I., Caputo, A., De Lazzari, C., De Lazzari, B., Cedrone, N., Madonna, R., Recchioni, T., Serino, G., Vizza, C. D., & **Badagliacca, R.** (2022). Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension. *Vascular pharmacology*, 145, 107024. <https://doi.org/10.1016/j.vph.2022.107024> (I.F. 5.77)
111. Mazzola M, Madonna R, **Badagliacca R**, Caterina R. Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside. *Vascul Pharmacol.* 2022;145:107022. doi:10.1016/j.vph.2022.107022 (I.F. 5.77)
112. Manzi G, Vizza CD, **Badagliacca R**. Comment on Topyła-Putowska et al. Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations. *J. Clin. Med.* 2021, 10, 3229. *J Clin Med.* 2022;11(12):3337. Published 2022 Jun 10. doi:10.3390/jcm11123337 (I.F. 4.96)
113. Salvioni, E., Mapelli, M., Bonomi, A., Magri, D., Piepoli, M., Frigerio, M., Paolillo, S., Corrà, U., Raimondo, R., Lagioia, R., **Badagliacca R.**, Filardi, P. P., Senni, M., Correale, M., Cicoira, M., Perna, E., Metra, M., Guazzi, M., Limongelli, G., Sinagra, G., ... MECKI Score Research Group (2022). Pick Your Threshold: A Comparison Among Different Methods of Anaerobic Threshold Evaluation in Heart Failure Prognostic Assessment. *Chest*, S0012-3692(22)01184-9. Advance online publication. <https://doi.org/10.1016/j.chest.2022.05.039> (I.F. 10.26)
114. Corrà U, Piepoli MF, Giordano A, Doni F, Magini A, Bonomi A, Salvioni E, Lagioia R, Limongelli G, Paolillo S, Magri D, Filardi PP, Sinagra G, Scardovi AB, Metra M, Senni M, Scrutinio D, Raimondo R, Emdin M, Cattadori G, Parati G, Re F, Cicoira M, Minà C, Correale M, Frigerio M, Perna E, Bussotti M, Battaia E, Guazzi M, Bandera F, **Badagliacca R**, Lenarda AD, Maggioni A, Passino C, Sciomer S, Pacileo G, Mapelli M, Vignati C, Clemenza F, Lombardi C, Agostoni P; MECKI score research group (see appendix). Revisiting a Prognosticating Algorithm from Cardiopulmonary Exercise Testing in Chronic Heart Failure (from the MECKI Score Population). *Am J Cardiol.* 2022 Oct 1;180:65-71. doi: 10.1016/j.amjcard.2022.06.034. Epub 2022 Jul 30. PMID: 35914972. (I.F. 2.77)
115. De Lazzari B, **Badagliacca R**, Filomena D, Papa S, Vizza CD, Capoccia M, De Lazzari C. CARDIOSIM©: The First Italian Software Platform for Simulation of the Cardiovascular System and Mechanical Circulatory and Ventilatory Support. *Bioengineering (Basel)*. 2022 Aug 11;9(8):383. doi: 10.3390/bioengineering9080383. PMID: 36004908; PMCID: PMC9404951. (I.F. 4.48)
116. Humbert M, Kovacs G, Hoeper MM, **Badagliacca R**, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J.* 2022

- statement on behalf of the International Consortium for Genetic Studies in PAH. *Eur Respir J.* 2023 Feb 23;61(2):2201471. doi: 10.1183/13993003.01471-2022. PMID: 36302552; PMCID: PMC9947314. (I.F. 24.3).
125. **Badagliacca R**, D'Alto M, Ghio S, Argiento P, Brunetti ND, Casu G, Cedrone N, Confalonieri M, Corda M, Correale M, D'Agostino C, De Michele L, Di Marino S, Filomena D, Galgano G, Greco A, Lombardi C, Manzi G, Mercurio V, Mulè M, Paciocco G, Papa S, Romeo E, Scelsi L, Stolfo D, Vitulo P, Vizza CD. Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension. *ERJ Open Res.* 2022 Nov 7;8(4):00298-2022. doi: 10.1183/23120541.00298-2022. PMID: 36382240; PMCID: PMC9638831. (I.F. 24.3).
 126. Marra AM, D'Agostino A, Salzano A, Basili S, D'Alto M, Bossone E, Cittadini A, Vizza CD, **Badagliacca R**. Impact of Hormonal-Anabolic Deficiencies in Idiopathic Pulmonary Arterial Hypertension. *Heart Fail Clin.* 2023 Jan;19(1):115-123. doi: 10.1016/j.hfc.2022.09.001. PMID: 36435567. (I.F. 4.65).
 127. Richter MJ, Fortuni F, Alenezi F, D'Alto M, **Badagliacca R**, Brunner NW, van Dijk AP, Douschan P, Gall H, Ghio S, Giudice FL, Grünig E, Haddad F, Howard L, Rajagopal S, Stens N, Stolfo D, Thijssen DHJ, Vizza CD, Zamanian RT, Zhong L, Seeger W, Ghofrani HA, Tello K. Imaging the right atrium in pulmonary hypertension: A systematic review and meta-analysis. *J Heart Lung Transplant.* 2023 Apr;42(4):433-446. doi: 10.1016/j.healun.2022.11.007. Epub 2022 Dec 9. PMID: 36610927. (I.F. 8.9).
 128. De Lazzari B, Capoccia M, Cheshire NJ, Rosendahl UP, **Badagliacca R**, De Lazzari C. Evaluation of Different Cannulation Strategies for Aortic Arch Surgery Using a Cardiovascular Numerical Simulator. *Bioengineering (Basel).* 2023 Jan 3;10(1):60. doi: 10.3390/bioengineering10010060. PMID: 36671632; PMCID: PMC9854437. (5.04).
 129. Pezzuto B, Piepoli M, Galotta A, Sciomer S, Zaffalon D, Filomena D, Vignati C, Contini M, Alimento M, Baracchini N, Apostolo A, Palermo P, Mapelli M, Salvioni E, Carriere C, Merlo M, Papa S, Campodonico J, **Badagliacca R**, Sinagra G, Agostoni P. The importance of re-evaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database. *Int J Cardiol.* 2023 Apr 1;376:90-96. doi: 10.1016/j.ijcard.2023.01.069. Epub 2023 Jan 27. PMID: 36716972. (I.F. 4.03).
 130. Severino P, D'Amato A, Prosperi S, Myftari V, Canuti ES, Labbro Francia A, Cestiè C, Maestrini V, Lavalle C, **Badagliacca R**, Mancone M, Vizza CD, Fedele F. Heart Failure Pharmacological Management: Gaps and Current Perspectives. *J Clin Med.* 2023 Jan 28;12(3):1020. doi: 10.3390/jcm12031020. PMID: 36769667; PMCID: PMC9917449. (I.F. 4.96).
 131. Manfrini V, **Badagliacca R**, Messaggio E, Poscia R, Torre R, Manunta P, Vizza CD. Exploratory study on the endogenous ouabain in idiopathic pulmonary arterial hypertension patients. *Ann Ist Super Sanita.* 2023 Jan-Mar;59(1):76-79. doi: 10.4415/ANN_23_01_11. PMID: 36974708. (I.F. 2.21).
 132. De Lazzari B, Capoccia M, **Badagliacca R**, Bozkurt S, De Lazzari C. IABP versus Impella Support in Cardiogenic Shock: "In Silico" Study. *J Cardiovasc Dev Dis.* 2023 Mar 26;10(4):140. doi: 10.3390/jcdd10040140. PMID: 37103019; PMCID: PMC10198323. (I.F. 4.41).
 133. Manzi G, Mariani MV, Filomena D, Poscia R, Severino P, Iaconelli A, Recchioni T, Madonna R, Vizza CD, **Badagliacca R**. Biobanks: The unmet need in heart failure management. *Vascul Pharmacol.* 2023 Jun;150:107179. doi: 10.1016/j.vph.2023.107179. Epub 2023 Apr 28. PMID: 37121386. (I.F. 4.0).
 134. Severino P, D'Amato A, Mancone M, Palazzuoli A, Mariani MV, Prosperi S, Myftari V, Lavalle C, Forleo GB, Birtolo LI, Caputo V, Miraldi F, Chimenti C, **Badagliacca R**, Maestrini V, Palmirotta R, Vizza CD, Fedele F. Protection against Ischemic Heart Disease:

143. Prosperi S, D'Amato A, Severino P, Myftari V, Monosilio S, Marchiori L, Zagordi LM, Filomena D, Di Pietro G, Birtolo LI, **Badagliacca R**, Mancone M, Maestrini V, Vizza CD. Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View. *Int J Mol Sci*. 2023 Sep 8;24(18):13848. doi: 10.3390/ijms241813848. PMID: 37762152; PMCID: PMC10530908. (I.F. 5.6).
144. Magrì D, Gallo G, Piepoli M, Salvioni E, Mapelli M, Vignati C, Fiori E, Muthukattil ML, Corrà U, Metra M, Paolillo S, Maruotti A, Di Loro PA, Senni M, Lagioia R, Scrutigno D, Emdin M, Passino C, Parati G, Sinagra G, Correale M, **Badagliacca R**, Sciomer S, Di Lenarda A, Agostoni P, Filardi PP. What about chronotropic incompetence in heart failure with mildly reduced ejection fraction? Clinical and prognostic implications from the Metabolic Exercise combined with Cardiac and Kidney Indexes score dataset. *Eur J Prev Cardiol*. 2024 Jan 25;31(2):263-271. doi: 10.1093/eurjpc/zwad338. Erratum in: *Eur J Prev Cardiol*. 2024 Jan 09;: PMID: 37890033. (I.F. 8.3).
145. Papa S, Scoccia G, Serino G, Adamo FI, Jabbour JP, Caputo A, Boromei M, Filomena D, Laviola D, Maggio E, Manzi G, Mihai A, Recchioni T, Sabusco A, Valeri L, Vinciullo S, Vizza CD, **Badagliacca R**. Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing. *J Clin Med*. 2023 Oct 29;12(21):6840. doi: 10.3390/jcm12216840. PMID: 37959305; PMCID: PMC10648828. (I.F. 4.4)
146. Lavallo C, Di Lullo L, Jabbour JP, Palombi M, Trivigno S, Mariani MV, Summaria F, Severino P, **Badagliacca R**, Miraldi F, Bellasi A, Vizza CD. New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events. *J Clin Med*. 2023 Nov 7;12(22):6956. doi: 10.3390/jcm12226956. PMID: 38002571; PMCID: PMC10672118. (I.F. 4.4).
147. Madonna R, Alberti M, Biondi F, Morganti R, **Badagliacca R**, Vizza CD, De Caterina R. Chronic thromboembolic pulmonary disease: Association with exercise-induced pulmonary hypertension and right ventricle adaptation over time: Chronic thromboembolic pulmonary disease and exercise pulmonary hypertension. *Eur J Intern Med*. 2023 Dec 1:S0953-6205(23)00417-X. doi: 10.1016/j.ejim.2023.11.021. Epub ahead of print. PMID: 38042668. (I.F. 8.0).
148. Improta R, Di Pietro G, Kola N, Birtolo LI, Colantonio R, Bruno E, Tocci M, Gian-sante A, Sannino M, Zullino V, Monosilio S, Cimino S, Maestrini V, Severino P, **Badagliacca R**, Lavallo C, Celli P, Saade W, Musto C, D'Ascenzo F, Miraldi F, Vizza CD, Sardella G, Mancone M. A Meta-Analysis of Short-Term Outcomes of TAVR versus SAVR in Bicuspid Aortic Valve Stenosis and TAVR Results in Different Bicuspid Valve Anatomies. *J Clin Med*. 2023 Nov 28;12(23):7371. doi: 10.3390/jcm12237371. PMID: 38068423; PMCID: PMC10707011. (I.F. 4.4).
149. De Lazzari B, Capoccia M, **Badagliacca R**, De Lazzari C. Modelling and Simulation of the Combined Use of IABP and Impella as a Rescue Procedure in Cardiogenic Shock: An Alternative for Non-Transplant Centres? *Bioengineering (Basel)*. 2023 Dec 17;10(12):1434. doi: 10.3390/bioengineering10121434. PMID: 38136025; PMCID: PMC10740626. (I.F. 4.48).
150. Morland K, Gerges C, Elwing J, Visovatti SH, Weatherald J, Gillmeyer KR, Sahay S, Mathai SC, Boucly A, Williams PG, Harikrishnan S, Minty EP, Hobohm L, Jose A, **Badagliacca R**, Lau EMT, Jing ZC, Vanderpool RR, Fauvel C, Leonidas Alves J Jr, Strange G, Pulido T, Qian J, Li M, Mercurio V, Zelt JGE, Moles VM, Cirulis MM, Nikkho SM, Benza RL, Elliott CG. Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group. *Pulm Circ*. 2023 Dec 21;13(4):e12317. doi: 10.1002/pul2.12317. PMID: 38144948; PMCID: PMC10739115. (I.F. 2.88).
151. **Badagliacca R**, Ghio S, Manzi G, Vizza CD. Right Ventricular/Pulmonary Artery Coupling in Patients With Heart Failure With Preserved Ejection Fraction: A Clue for Pul-

Reviewer for the following Journals:

- Giornale Italiano di Cardiologia, since 2002.
- Heart, since 2016.
- Journal of Heart and Lung Transplantation, since 2016.
- International Journal of Cardiology, since 2017.
- Pulmonary Circulation, since 2017.
- European Respiratory Journal, since 2019.
- Journal of the American College of Cardiology – Cardiovascular Imaging, since 2020.
- European Heart Journal, since April 2021.

Member of the Editorial Board for Pulmonary Circulation since 2017 (I.F. 2.2).

Associate Editor for Journal of Clinical Medicine since March 2021 (I.F. 4.2).

Member of the Editorial Board for Vascular Pharmacology (I.F. 5.6) since 2021.

Associate Editor of Frontiers in Cardiovascular Medicine journal (I.F. 5.6) since 2023.

Confirma 6/3/2025

